21 CFR 60.28
§ 60.28 Time frame for determining regulatory review periods.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 60.28, § 60.28 Time frame for determining regulatory review periods, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/83556
- Permanent ID
ys:prov:83556@1- SHA-256
39c83ae5ded61da591e2f6f0a1d7aa274a1b0ce3f7c1c4c0ee32f05a71b0d647
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) FDA will determine the regulatory review period for a product within 30 days of the receipt of a written request from PTO for such a determination and a copy of the patent term restoration application.
(b) FDA may extend the 30-day period if:
(1) A related FDA action that may affect the regulatory review period determination is pending; or
(2) PTO requests that FDA temporarily suspend the determination process; or
(3) PTO or FDA receives new information about the product that warrants an extension of the time required for the determination of the regulatory review period.
(c) This section does not apply to applications withdrawn by the applicant or applications that PTO determines are ineligible for patent term restoration.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.